Immunotherapy最新文献

New onset of hypertension associated with immune checkpoint inhibitor therapy in cancer patients. 癌症患者新发高血压与免疫检查点抑制剂治疗相关

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-16 DOI: 10.1080/1750743X.2025.2504868

HangYu Watson, Nolan Holley, Tabot Ntoung Nkongho, Brijesh Patel

{"title":"New onset of hypertension associated with immune checkpoint inhibitor therapy in cancer patients.","authors":"HangYu Watson, Nolan Holley, Tabot Ntoung Nkongho, Brijesh Patel","doi":"10.1080/1750743X.2025.2504868","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2504868","url":null,"abstract":"Aim: To evaluate whether immune checkpoint inhibitor (ICI) therapy is associated with a higher incidence of hypertension (HTN) among cancer patients compared to those not treated with ICIs.Materials & methods: This retrospective cohort study utilized data from the TriNetX Research Network, a global database of de-identified electronic health records. Adult patients (≥18 years) with lung, breast, colon, kidney, or skin cancer were categorized based on ICI treatment. Patients with preexisting hypertension were excluded. Propensity score matching (1:1) based on demographics and comorbidities yielded two balanced cohorts of 24,956 patients each. The primary outcome was the incidence of hypertension within one year of cancer diagnosis.Results: The incidence of hypertension was significantly higher in the ICI group (13.2%) compared to the non-ICI group (9.7%). The risk ratio was 1.356 (95% CI: 1.271-1.446), and the odds ratio was 1.410 (95% CI: 1.311-1.516), both with p < 0.001. Kaplan-Meier analysis showed lower hypertension-free survival in the ICI group (log-rank p < 0.001; HR = 1.071).Conclusions: ICI therapy is significantly associated with an increased risk of developing hypertension. These findings support the need for routine cardiovascular monitoring in patients receiving ICI treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug evaluation: mepolizumab in chronic obstructive pulmonary disease. 药物评价：mepolizumab治疗慢性阻塞性肺疾病。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-14 DOI: 10.1080/1750743X.2025.2504326

Matheus Rabahi, Ian D Pavord

{"title":"Drug evaluation: mepolizumab in chronic obstructive pulmonary disease.","authors":"Matheus Rabahi, Ian D Pavord","doi":"10.1080/1750743X.2025.2504326","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2504326","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality globally, marked by persistent respiratory symptoms and exacerbations. It is now acknowledged to be a heterogeneous disease with respect to clinical expression and key driving mechanisms. Standard therapies, including bronchodilators and corticosteroids, often fail to adequately control symptoms and exacerbations in patients and there is an important unmet need for new treatments. There has been encouraging progress with biological treatments for patients with COPD and type-2 airway inflammation, a phenotype found in approximately 40% of COPD cases. The first of these, Mepolizumab, is a monoclonal antibody targeting interleukin-5 (IL-5), and thereby reducing blood and tissue eosinophil numbers. Here we review the initial clinical trial data with mepolizumab in type-2 high COPD. We suggest that the modest efficacy seen in patients with severe disease may not be reflective of the impact of treatment in patients with active type-2 inflammation and less associated lung and extra-pulmonary damage. We suggest that the way forward is to assess whether clinically important modification of disease course occurs with treatment in patients with high disease activity and low associated damage.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence for optimal treatment of immune-related adverse events needed - should we use extracorporeal photopheresis? 需要最佳治疗免疫相关不良事件的证据——我们应该使用体外光疗吗？

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-12 DOI: 10.1080/1750743X.2025.2498316

L Heinzerling

引用次数: 0

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary. 评估COMPACT研究中风湿病患者使用SDZ ETN（一种依那西普生物类似药）的实际治疗效果：简单的语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-12 DOI: 10.1080/1750743X.2025.2493039

Marc Schmalzing, Herbert Kellner, Ayman Askari, Javier de Toro Santos, Julio Cesar Vazquez Perez-Coleman, Rosario Foti, Sławomir Jeka, Yannick Allanore, Peter Peichl, Martin Oehri, Neil Betteridge, Cristofer Salvati, Elisa Romero, Ines Brueckmann, Tom Sheeran

引用次数: 0

Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model. 在结直肠癌模型中，溶瘤呼肠孤病毒联合PD1-PDL1抑制剂增强CEA免疫治疗的效果。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-12 DOI: 10.1080/1750743X.2025.2501926

Atefeh Yari, Seyed Younes Hosseini, Sanaz Asiyabi, Nazila Hajiahmadi, Mohammad Farahmand, Taravat Bamdad

{"title":"Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.","authors":"Atefeh Yari, Seyed Younes Hosseini, Sanaz Asiyabi, Nazila Hajiahmadi, Mohammad Farahmand, Taravat Bamdad","doi":"10.1080/1750743X.2025.2501926","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2501926","url":null,"abstract":"Aim: The effectiveness of immunotherapy with tumor associated antigen vaccines can be enhanced by combining oncolytic viruses with immune checkpoint inhibitors. This study evaluates the efficacy of oncolytic reovirus in combination with an adenovector expressing carcinoembryonic antigen (Ad-CEA) and a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in a mouse model.Methods: Mice bearing CEA-expressing CT26 tumor cells were immunized with Ad-CEA along with a PD-1/PD-L1 inhibitor. Subsequently, three doses of reovirus were injected into the tumors. Tumor size, histopathological examination, CD8 and FOXP3 expression, the cytotoxicity of spleen T cell lymphocytes, and the secretion of Interferon-γ (IFN-γ) and Tumor necrosis factor- α (TNF-α) were examined.Results: The triple therapy used in this study resulted in the lowest tumor growth and the highest level of cytotoxic immunity. The Foxp3 levels in the tumor microenvironment and TNF-α secretion decreased compared to other control groups. Additionally, this group exhibited the lowest number of mitotic figures and the highest amount of tumor-infiltrating lymphocytes.Conclusion: The combination of tumor vaccines with oncolytic viruses significantly improves treatment efficacy. Furthermore, inhibiting the PD-1/PD-L1 interaction during vaccination and also with virotherapy enhances immunovirotherapy by reducing immunosuppressive effects and stimulating the immune system, leading to improved therapeutic outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment. 美沙拉嗪缓解鼻咽癌患者在替利单抗治疗后腹泻的病例报告。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-11 DOI: 10.1080/1750743X.2025.2504323

Xiaomei Zhou, Yu Shu, Xi Chen, Bo Luo

{"title":"A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment.","authors":"Xiaomei Zhou, Yu Shu, Xi Chen, Bo Luo","doi":"10.1080/1750743X.2025.2504323","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2504323","url":null,"abstract":"Immunotherapy has become a significant research focus for cancer treatment in recent years because it can generate enduring immunological responses and has promising therapeutic potential. Nevertheless, excessive stimulation of the immune system may adversely affect healthy organs, which can lead to immune-related toxicities, including gastrointestinal, pulmonary, hepatic, and dermatological toxicities. Among them, gastrointestinal toxicity induced by the immune response is the most common. Immune-associated enteritis has an incidence rate of 8%-27% and is one of the most prevalent forms of gastrointestinal toxicity. Tislelizumab is an approved first-line treatment for individuals with recurrent or metastatic nasopharyngeal cancer functioning as an inhibitor of PD-1. Here, we report a patient with nasopharyngeal carcinoma who developed bloody stools and diarrhea after two cycles of tislelizumab. Abdominal CT revealed intestinal wall thickening with inflammatory exudation. Congestion, edema, and mucosal punctate ulcers were discovered during the colonoscopy. Histopathology confirmed active mucosal inflammation. The initial treatment with loperamide, bifidobacterium tetrad, and norfloxacin failed, but the symptoms improved significantly after switching to metronidazole, mesalazine, and methylprednisolone. This article reviewed a case of immunological enteritis triggered by tislelizumab, demonstrating that mesalazine can markedly alleviate the symptoms of immune-associated enteritis, aiming to enhance future clinical efforts regarding tislelizumab-induced immunological enteritis.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.7,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. 接受免疫检查点抑制剂治疗的癌症患者关节痛：一项系统综述和荟萃分析。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-08 DOI: 10.1080/1750743X.2025.2501519

Yoshito Nishimura, Jonathan Estaris, Mako Koseki, Evelyn Elias, Fnu Chesta, Kensuke Takaoka, Theresa Shao, Nobuyuki Horita, Yu Fujiwara

{"title":"Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.","authors":"Yoshito Nishimura, Jonathan Estaris, Mako Koseki, Evelyn Elias, Fnu Chesta, Kensuke Takaoka, Theresa Shao, Nobuyuki Horita, Yu Fujiwara","doi":"10.1080/1750743X.2025.2501519","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2501519","url":null,"abstract":"Background: Although immune checkpoint inhibitors (ICIs) are widely used for patients with cancer, evidence of the impact of ICIs on the incidence of arthralgia remains limited.Objective: To evaluate the impact of ICIs on arthralgia incidences in patients with cancer.Methods: We performed a systematic review to identify phase 3 randomized control trials (RCTs) evaluating ICIs in patients with cancer and reporting the incidence of arthralgia. We performed a meta-analysis to pool odds ratios (ORs) of any grade and grade 3-5 arthralgia.Results: Forty RCTs (n = 26,610) were included. The incidence of any-grade and grade 3-5 treatment-related arthralgia was 12.0% (n = 1,125/9,395) and 0.54% (n = 47/8,723). The addition of an ICI to systemic therapy, such as chemotherapy, significantly increased any-grade (OR 1.32, 95% CI: 1.13-1.54, p = 0.001) and grade 3-5 arthralgia (OR 1.78, 95% CI: 1.08-2.94, p = 0.02) with low heterogeneity among ICI subtype subgroups (I2 = 0%). ICI monotherapy was associated with higher incidences of arthralgia than non-taxane (OR 6.83, 95% CI: 3.05-15.30, p < 0.001) but not than taxane chemotherapy (OR 0.74, 95% CI: 0.44-1.24, p = 0.25).Conclusions: These results could guide oncologists to assess arthralgia in patients receiving ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging of brain metastases treated with immune checkpoint inhibitors. 免疫检查点抑制剂治疗脑转移瘤的影像学研究。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-08 DOI: 10.1080/1750743X.2025.2501931

Imren Özdamar, Sophie H A E Derks, Astrid A M van der Veldt

引用次数: 0

Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease. 评估阿替利单抗作为慢性移植物抗宿主病的治疗选择。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-08 DOI: 10.1080/1750743X.2025.2501928

Tania Dexter, Chloe Anthias, Emma Nicholson

引用次数: 0

Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy. 免疫检查点抑制剂和化疗对胃癌患者Khorana风险评分的影响

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-07 DOI: 10.1080/1750743X.2025.2501922

Junmin Song, Ahmed Ashraf Morgan, Jaeun Ahn, Wing Fai Li, Yu Chang, Yu-Cheng Chang, Muhammad Fahimuddin, Kuan-Yu Chi, Lawrence W Wu, Cho-Han Chiang

{"title":"Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy.","authors":"Junmin Song, Ahmed Ashraf Morgan, Jaeun Ahn, Wing Fai Li, Yu Chang, Yu-Cheng Chang, Muhammad Fahimuddin, Kuan-Yu Chi, Lawrence W Wu, Cho-Han Chiang","doi":"10.1080/1750743X.2025.2501922","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2501922","url":null,"abstract":"Introduction: Patients with gastric cancer are at a high risk of venous thromboembolism (VTE), and immune checkpoint inhibitors (ICIs) may further increase this risk. While the Khorana Risk Score (KRS) has been validated primarily in chemotherapy-treated populations, its utility in ICI-treated patients remains unclear.Methods: Using the TriNetX Global Collaborative Network, we analyzed data from 2782 patients with gastric cancer treated with ICIs. Patients were stratified into high-risk (KRS ≥3) and intermediate-risk (KRS = 2) groups based on pre-treatment laboratory values and BMI. Cox proportional-hazards analyses were performed to evaluate the association between KRS and outcomes, including VTE, all-cause mortality, and arterial thrombosis, over a one-year follow-up period.Results: High-risk patients had a 26% higher risk of VTE (HR: 1.26, [95% CI: 1.06-1.50]) and a 43% higher risk of all-cause mortality (HR: 1.43, [95% CI: 1.27-1.62]) compared to intermediate-risk patients. The incidence of deep vein thrombosis (DVT) was also significantly higher in the high-risk group (HR: 1.27, [95% CI: 1.01-1.59]), but no significant differences were observed for pulmonary embolism (PE) or arterial thrombosis.Conclusion: These findings suggest the KRS may effectively stratify VTE risk and mortality in gastric cancer patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0